Document 0716
 DOCN  M9620716
 TI    A macromolecular multicomponent peptide vaccine prepared using the
       glutaraldehyde conjugation method with strong immunogenicity for HIV-1.
 DT    9602
 AU    Hamajima K; Bukawa H; Fukushima J; Kawamoto S; Kaneko T; Sekigawa K;
       Tanaka S; Tsukuda M; Okuda K; Department of Bacteriology, Yokohama City
       University School of; Medicine, Japan.
 SO    Clin Immunol Immunopathol. 1995 Dec;77(3):374-9. Unique Identifier :
       AIDSLINE MED/96080367
 AB    The immunogenicity of a newly constructed macromolecular multicomponent
       peptide vaccine candidate against human immunodeficiency virus type 1
       (HIV-1) was compared with that of previously reported vaccine
       candidates. This vaccine candidate is composed of a macromolecular
       multicomponent peptide complex consisting of three V3 region peptides,
       one Gag region peptide, and CD4-binding site peptide and was constructed
       using the multiple-antigen peptide and glutaraldehyde methods. Sera from
       rabbits immunized with this newly constructed vaccine showed strong
       antibody titers against each constituent peptide antigen. Furthermore,
       these antibodies exhibited strong neutralizing and antifusion activity
       toward HIV-1IIB, HIV-1MN, and fresh isolates from Japanese
       HIV-seropositive individuals. These results show that this new vaccine
       candidate has the capacity to induce strong, polyvalent immunogenicity
       and therefore may prove to be a powerful peptide vaccine against HIV-1
       infection.
 DE    Amino Acid Sequence  Animal  AIDS Vaccines/*IMMUNOLOGY  Enzyme-Linked
       Immunosorbent Assay  Glutaral/*PHARMACOLOGY  Human  HIV
       Antibodies/BIOSYNTHESIS  HIV Antigens/CHEMISTRY/IMMUNOLOGY/PHARMACOLOGY
       HIV-1/*IMMUNOLOGY  Molecular Sequence Data  Neutralization Tests
       Rabbits  Support, Non-U.S. Gov't  Vaccines, Synthetic/CHEMISTRY/DRUG
       EFFECTS/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).